TABLE 1.
TSE sources transmitted to TgOvPrP4 ovine transgenic micea
| TSE source | Breed | PrP genotypeb | Survival period (days p.i. [mean ± SD]) | PrPd-positive micec |
|---|---|---|---|---|
| Sheep isolates | ||||
| CH1641 | Cheviot | AxQ/AxQ | 245 ± 17 (p1) | 12/12 |
| 220 ± 31 (p2) | 11/11 | |||
| O100 | Manech tête rousse | VRQ/VRQ | 364 ± 61 | 12/12 |
| O104 | Manech tête rousse | VRQ/VRQ | 248 ± 50 (p1) | 10/10 |
| 204 ± 6 (p2 from a PrPres l-type mouse) | 13/13 | |||
| 238 ± 29 (p2 from a PrPres h-type mouse) | 13/13 | |||
| TR316211 | Unknown | ARQ/ARQ | 235 ± 26 | 8/8 |
| Experimental strainsd | ||||
| Chandler | 396 ± 100 | 9/9 | ||
| C506M3 | 333 ± 26 | 11/11 | ||
| 87V | 258 ± 44 | 10/10 | ||
| 79A | 342 ± 20 | 12/12 | ||
| BSE | 375 ± 51 | 12/12 |
a
Incubation periods of the disease and results of detection of disease-associated PrP by Western blotting or immunohistochemistry are shown.
b
Amino acids 136, 154, and 171.
c
Number of positive mice/number of mice examined by Western blotting or immunohistochemistry.
d
Second passage in TgOvPrP4 mice from previously reported primary passage (2).